# CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

> **NCT01746173** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- T-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Etoposide
- **DRUG:** Prednisone
- **DRUG:** Filgrastim
- **DRUG:** Plerixafor
- **PROCEDURE:** Stem Cell Collection
- **DRUG:** Palifermin
- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT01746173
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Slow accrual and futility
- **Last updated:** 2023-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01746173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01746173, "CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01746173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*